Research Analysts Offer Predictions for UTHR FY2027 Earnings

Key Points

• HC Wainwright has downgraded its FY2027 EPS estimate for United Therapeutics from $28.77 to $28.37, while maintaining a "Buy" rating and a price target of $500.00.
• The company's latest quarterly earnings report showed an EPS of $6.41, missing the consensus estimate by $0.39, despite a revenue increase of 11.7% year-over-year.
• Multiple analysts have set price targets for United Therapeutics, with targets ranging from $330.00 to $575.00, indicating a positive outlook on the stock.

United Therapeutics Corporation (NASDAQ:UTHR - Free Report) - Equities researchers at HC Wainwright dropped their FY2027 EPS estimates for United Therapeutics in a note issued to investors on Friday, September 5th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings per share of $28.37 for the year, down from their previous forecast of $28.77. HC Wainwright has a "Buy" rating and a $500.00 price objective on the stock. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business's revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the previous year, the business earned $5.85 earnings per share.

Other equities research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. reduced their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $560.00 and gave the company a "buy" rating in a research report on Thursday. Cantor Fitzgerald reiterated an "overweight" rating on shares of United Therapeutics in a research report on Thursday, August 14th. Oppenheimer increased their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a research report on Friday. Finally, Jefferies Financial Group increased their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Nine equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $429.62.

United Therapeutics Stock Up 5.3%

Shares of NASDAQ UTHR opened at $400.52 on Monday. The firm has a 50-day simple moving average of $307.69 and a 200-day simple moving average of $305.37. The stock has a market capitalization of $18.07 billion, a price-to-earnings ratio of 15.63, a price-to-earnings-growth ratio of 6.11 and a beta of 0.62. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $436.95.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in shares of United Therapeutics during the first quarter valued at about $313,000. Allianz Asset Management GmbH increased its position in shares of United Therapeutics by 96.9% during the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock valued at $20,832,000 after acquiring an additional 33,254 shares during the last quarter. LPL Financial LLC increased its position in shares of United Therapeutics by 77.3% during the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after acquiring an additional 11,007 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after acquiring an additional 376 shares during the last quarter. Finally, Concurrent Investment Advisors LLC acquired a new stake in shares of United Therapeutics during the first quarter valued at about $227,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Christopher Causey sold 3,000 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $423.21, for a total transaction of $1,269,630.00. Following the completion of the sale, the director directly owned 4,865 shares in the company, valued at approximately $2,058,916.65. This trade represents a 38.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $385.21, for a total transaction of $4,237,310.00. Following the sale, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $14,168,409.01. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 106,181 shares of company stock valued at $35,537,239 in the last quarter. Insiders own 10.30% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.